Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment-Reference-Cited by-同舟云学术

Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment

Published:2021-04 Issue: Volume:Volume 15 Page:1433-1442
ISSN:1177-5483
Container-title:Clinical Ophthalmology
language:en
Short-container-title:OPTH

Author:

Steeples Laura R,Pockar Sasa,Jones Nicholas P,Leal Inês^ORCID

Publisher

Informa UK Limited

Subject

Ophthalmology

Reference36 articles.

1. Treating Chronic Noninfectious Posterior Segment Uveitis

2. Multicenter Study of Intravitreal Dexamethasone Implant in Noninfectious Uveitis: Indications, Outcomes, and Reinjection Frequency

3. Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

4. Clinical Outcomes of Intravitreal Preservative-Free Triamcinolone Preparation (Triesence®) for Cystoid Macular Oedema and Inflammation in Patients with Uveitis

5. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in the diagnosis and management of Behçet’s syndrome uveitis;Expert Review of Ophthalmology;2024-08-17

2. The effectiveness of the 0.19 mg fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience;Journal of Ophthalmic Inflammation and Infection;2024-06-04

3. Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations;Journal of Ophthalmic Inflammation and Infection;2024-05-30

4. Long-Term Results of 0.19mg Fluocinolone Acetonide Insert for Treatment of Non-Infectious Uveitis in Clinical Practice;Ocular Immunology and Inflammation;2023-09-01

5. Advances in development of exosomes for ophthalmic therapeutics;Advanced Drug Delivery Reviews;2023-08